Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024 Investor Brand Network - Wed Apr 24, 9:40AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event Investor Brand Network - Tue Apr 23, 10:04AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals’ (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients Investor Brand Network - Tue Apr 16, 9:16AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update Investor Brand Network - Wed Apr 3, 8:51AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Board Investor Brand Network - Tue Mar 19, 9:01AM CDT

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage...

ROIV : 11.06 (+1.65%)
CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricing Investor Brand Network - Tue Jan 30, 9:55AM CST

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors Investor Brand Network - Fri Jan 19, 12:50PM CST

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification Investor Brand Network - Tue Dec 19, 2023

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals’ (NASDAQ: CNSP) Interim Analysis on Berubicin Trial Showing Promising Results Investor Brand Network - Thu Dec 7, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the...

CNSP : 0.2050 (+0.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study Investor Brand Network - Mon Nov 27, 2023

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced...

CNSP : 0.2050 (+0.49%)

Barchart Exclusives

European Commodities: After Asian Supply Shock, What's Next for Nickel? Barchart - 1 hour ago
European Commodity Markets Weekly 25 April 2024 Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot